Loading patent…
AssigneeMount Sinai School of Medicine
InventorsAndrei Egorov, Thomas Muster, Adolfo Garcia-Sastre, Peter Palese, Sabine Brandt
Estimating the term…
The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.
An attenuated genetically engineered influenza A virus with an interferon-inducing phenotype containing a knockout of the NS1 gene segment.
An attenuated genetically engineered influenza A virus containing a deletion of the entire NS1 gene segment which is capable of infecting and replicating in an interferon (IFN) deficient cell line.
A vaccine comprising an attenuated genetically engineered influenza A virus containing a complete deletion in its NS1 gene segment in a suitable pharmaceutical formulation.
Dependencies are inferred from the claim text.